Syndax Pharmaceuticals, Inc. filed an 8-K with the U.S. Securities and Exchange Commission on November 2, 2026, disclosing the retirement of Chief Financial Officer Keith A. Goldan and the appointment of Aaron A. Ondrey as his successor, both effective November 9, 2026, alongside the company's financial results for the quarter ended September 30, 2026.

Key Highlights

  • CFO transition: Keith A. Goldan will retire as Chief Financial Officer, principal accounting and financial officer, and treasurer effective November 9, 2026, after which he will serve as an advisor for an interim period.
  • Incoming CFO: Aaron A. Ondrey will join as Chief Financial Officer, principal accounting and financial officer, and treasurer, also effective November 9, 2026.
  • Base salary: Ondrey's employment agreement provides for an annual base salary of $543,000.
  • Annual bonus target: Ondrey's target bonus is set at 45% of his base salary.
  • Stock option grant: Ondrey will receive a one-time option to purchase 270,000 shares of common stock, exercisable at the closing price on November 9, 2026, the date of grant.
  • Vesting schedule: Twenty-five percent of the option shares vest on the one-year anniversary of the vesting commencement date, with 1/48th vesting monthly over the following 36 months.
  • Quarterly results: The company also furnished a press release and presentation covering financial results for the quarter ended September 30, 2026.

Ondrey's Appointment and Goldan's Transition at Syndax Pharmaceuticals

According to the filing, Syndax Pharmaceuticals (NASDAQ:SNDX) announced that Keith A. Goldan's retirement as CFO takes effect on November 9, 2026. Prior to that date, the filing states, Goldan will assist with the transition of his responsibilities, and his compensation as an advisor "will be materially consistent with his current compensation." The company's board of directors appointed Ondrey as principal accounting and financial officer and treasurer simultaneously with his appointment as CFO.

The filing details Ondrey's professional background: he most recently served as Chief Financial Officer of Beren Therapeutics, a private company, since September 2025. Before that, he was CFO of Rocket Pharmaceuticals from March 2024 until September 2025, CFO of Mirati Therapeutics from September 2023 until January 2024, and Senior Vice President, FP&A, at Mirati from July 2022 through August 2023. From January 2020 until July 2022, he served as Vice President, Finance, at Arena Pharmaceuticals. He also previously held financial roles at Alexion Pharmaceuticals and Regeneron Pharmaceuticals. Ondrey holds a B.S. in Finance from Case Western Reserve University, according to the filing.

The employment agreement, dated November 2, 2026, also specifies severance terms. The filing discloses that if Ondrey is terminated without "cause" or resigns for "good reason," he is entitled to a lump sum equal to nine months of base salary, up to nine months of health insurance continuation, and accelerated vesting on equity awards that would have vested within the following 12 months. In a change-in-control scenario occurring within three months prior to or 12 months after such event, the severance increases to 18 months of base salary plus 100% of the greater of his average annual target bonus for the preceding three years or his then-current target bonus, 18 months of health insurance continuation, and full accelerated vesting on all unvested options and other equity awards, according to the filing.

What Was Disclosed

Syndax Pharmaceuticals disclosed the CFO retirement of Keith A. Goldan and the hiring of Aaron A. Ondrey, both effective November 9, 2026, along with the key terms of Ondrey's employment agreement and the company's third-quarter 2026 financial results.